Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite allergen extract
- Development stage
- Approved
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual, Subcutaneous
01
Overview
House dust mite allergen extract is a biologic immunotherapy used to treat allergic rhinitis, with or without conjunctivitis, caused by sensitization to house dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus)[1][2][5]. It is available as sublingual tablets (Odactra, Actair) and as standardized injectable extracts. The mechanism of action involves exposing the immune system to controlled amounts of the relevant allergens to induce tolerance; this leads to increased IgG antibodies that compete with IgE antibodies responsible for allergy symptoms and may also modulate T-cell responses[8]. The primary indication is for patients with confirmed house dust mite-induced allergic rhinitis. Odactra is approved for use in individuals aged 5 through 65 years[5].
- Brand names
- OdactraActair
- Other names
- house dust mite allergen extractDermatophagoides farinae and Dermatophagoides pteronyssinus allergen extract
Beyond the preview
Go deeper on House dust mite allergen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on House dust mite allergen extract.